





**A****B**

**Figure S1. Gating strategy for the polyfunctional assay. (A)** Physical parameters are used to exclude doublets. hCD45<sup>+</sup> lymphocytes are then separated from mCD45<sup>+</sup> lymphocytes and CD8<sup>+</sup> and CD4<sup>+</sup> T cells are gated within hCD45<sup>+</sup>CD3<sup>+</sup> cells. **(B)** Human CD8<sup>+</sup> and CD4<sup>+</sup> T cells further analyzed for the production of IL2, TNF $\alpha$  and IFN $\gamma$ . Fluorescence Minus One (FMO) are used as negative control to set up gating.

**A****B**

**Figure S2. Boosted PBMC-hu-NSG-A2 model. (A)** Body weight of mice in figure 4C & 4D expressed as the percentage of the initial weight. Signs of GvHD are typically manifested when 25% body weight loss is reached. **(B)** Engraftment of human CD45<sup>+</sup> cells in the blood of mice in figure 4C & 4D was analyzed by flowcytometry at day 17 and day 40 after PBMCs injection.